B. Abrahamsen

First name
Last name
Khalid, S., Calderon-Larranaga, S., Sami, A., Hawley, S., Judge, A., Arden, N., et al. (2022). Comparative risk of acute myocardial infarction for anti-osteoporosis drugs in primary care: a meta-analysis of propensity-matched cohort findings from the UK Clinical Practice Research Database and the Catalan SIDIAP Database. Osteoporos Int. http://doi.org/10.1007/s00198-021-06262-1
Robinson, D. E., Ali, M. S., Pallares, N., Tebe, C., Elhussein, L., Abrahamsen, B., et al. (2020). Safety of oral bisphosphonates in moderate-to-severe chronic kidney disease: a bi-national cohort analysis. J Bone Miner Res. http://doi.org/10.1002/jbmr.4235
Alarkawi, D., Ali, M. S., Bliuc, D., Pallares, N., Tebe, C., Elhussein, L., et al. (2020). Oral bisphosphonate use and all-cause mortality in patients with moderate-severe (grade 3B-5D) chronic kidney disease: a population-based cohort study. J Bone Miner Res. http://doi.org/10.1002/jbmr.3961
Khalid, S., Reyes, C., Ernst, M., Delmestri, A., Toth, E., Libanati, C., et al. (2021). One- and 2-year incidence of osteoporotic fracture: a multi-cohort observational study using routinely collected real-world data. Osteoporos Int. http://doi.org/10.1007/s00198-021-06077-0
Khalid, S., i, P. -M. \ \, El-Hussein, L., Delmestri, A., Ernst, M., Smith, C., et al. (2021). Predicting Imminent Fractures in Patients With a Recent Fracture or Starting Oral Bisphosphonate Therapy: Development and International Validation of Prognostic Models. J Bone Miner Res. http://doi.org/10.1002/jbmr.4414
Robinson, D. E., Ali, M. S., . Y. Strauss, V., Elhussein, L., Abrahamsen, B., Arden, N. K., et al. (2021). Bisphosphonates to reduce bone fractures in stage 3B+ chronic kidney disease: a propensity score-matched cohort study. Health Technol Assess. http://doi.org/10.3310/hta25170